Extrapyramidal signs (EPS) are frequent in Alzheimer’s disease (AD) and core manifestation of related diseases, i.e., dementia with Lewy bodies and Parkinson’s disease; furthermore, Lewy bodies and AD-type pathology occur in all three conditions.
Objective:
To identify clusters of EPS progression over time and their clinical and neuropathological correlates.
Methods:
3,502 AD patients with longitudinal assessment from the National Alzheimer’s Coordinating Center database were included; 394 provided neuropathological data. k-means algorithm was employed to identify clusters of EPS progression and those were compared in terms of cognitive profile, neuropsychiatric features and neuropathological findings.
Results:
Three clusters of EPS progression were identified: no/low (n = 1,583), medium (n = 1,259), and high (n = 660) EPS burden. Compared to those with no/low and medium EPS, those with high EPS had greater cognitive and neuropsychiatric impairment, specifically hallucinations. Despite similar AD-pathology across the three clusters, the high EPS cluster had a significantly number of subjects diagnosed with dementia with Lewy bodies.
Conclusions:
Cluster analysis of EPS progression over time identified different subgroups of AD patients with distinct clinical and neuropathological features.
Alzheimer’s Association (2013) 2013 Alzheimer’s disease facts and figures. Alzheimers Dement9, 208–245.
2.
PortetF, ScarmeasN, CosentinoS, HelznerEP, SternY
(2009) Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study. Arch Neurol66, 1120–1126.
3.
MangoneC
(2003) [Clinical heterogeneity of Alzheimer’s disease. Different clinical profiles can predict the progression rate]. Rev Neurol38, 675–681.
4.
PaulsenJS, SalmonD, ThalL, RomeroR, Weisstein–JenkinsC, GalaskoD, HofstetterC, ThomasR, GrantI, JesteD
(2000) Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology54, 1965–1971.
5.
RopackiSA, JesteDV
(2005) Epidemiology of and risk factors for psychosis of Alzheimer’s disease: A review of 55 studies published from 1990 to 2003. Am J Psychiatry162, 2022–2030.
ZhuK, HiltenJJ, PutterH, MarinusJ
(2013) Risk factors for hallucinations in Parkinson’s disease: Results from a large prospective cohort study. Mov Disord28, 755–762.
SwerdlowRH, NewellKL
(2012) “Untangling” the relationship between Alzheimer disease and dementia with Lewy bodies. Neurology6, 1938–1939.
10.
GenoliniC, FalissardB
(2011) KmL: A package to cluster longitudinal data. Comput Methods Programs Biomed104, e112–e121.
11.
BeeklyDL, RamosEM, LeeWW, DeitrichWD, JackaME, WuJ, HubbardJL, KoepsellTD, MorrisJC, KukullWANIA Alzheimer’s Disease Centers2007) The National Alzheimer’s Coordinating Center (NACC) database: The uniform data set. Alzheimer Dis Assoc Disord21, 249–258.
12.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM
(1984) Clinical diagnosis of Alzheimer’s disease Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–939.
13.
GoetzCG, TilleyBC, ShaftmanSR, StebbinsGT, FahnS, Martinez-MartinP, PoeweW, SampaioC, SternMB, DodelR, DuboisB, HollowayR, JankovicJ, KulisevskyJ, LangAE, LeesA, LeurgansS, LeWittPA, NyenhuisD, OlanowCW, RascolO, SchragA, TeresiJA, van HiltenJJ, LaPelleN,
Movement Disorder Society UPDRS Revision Task Force
(2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord23, 2129–2170.
14.
KauferDI, CummingsJL, KetchelP, SmithV, MacMillanA, ShelleyT, LopezOL, DeKoskyST
(2000) Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci12, 233–239.
15.
FolsteinMF, FolsteinSE, McHughPR
(1975) “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
16.
MorrisJC
(1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology43, 2412–2414.
17.
MirraS, HartMN, TerryR
(1993) Making the diagnosis of Alzheimer’s disease. A primer for practicing pathologists. Arch Pathol Lab Med117, 132–144.
18.
BraakH, AlafuzoffI, ArzbergerT, KretzschmarH, Del TrediciK
(2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol112, 389–404.
19.
CalinskiT, HarabaszJ
(1974) A dendrite method for cluster analysis. Commun Stat Theory Methods3, 1–27.
20.
ZegerSL, LiangK-Y
(1992) An overview of methods for the analysis of longitudinal data. Stat Med11, 1825–1839.
21.
RichardsM, MarderK, BellK, DooneiefG, MayeuxR, SternY
(1991) Interrater reliability of extrapyramidal signs in a group assessed for dementia. Arch Neurol48, 1147–1149.
HansenL, SalmonD, GalaskoD, MasliahE, KatzmanR, DeTeresaR, ThalL, PayM, HofstetterR, KlauberM, et al. (1990) The Lewy body variant of Alzheimer’s disease A clinical and pathologic entity. Neurology40, 1–8.
24.
SternY, JacobsD, GoldmanJ, Gomez-TortosaE, HymanBT, LiuY, TroncosoJ, MarderK, TangMX, BrandtJ, AlbertM
(2001) An investigation of clinical correlates of Lewy bodies in autopsy-proven Alzheimer disease. Arch Neurol58, 460–465.
25.
LiuY, SternY, ChunMR, JacobsDM, YauP, GoldmanJE
(1997) Pathological correlates of extrapyramidal signs in Alzheimer’s disease. Ann Neurol41, 368–374.
26.
SchneiderJA, LiJ-L, LiY, WilsonRS, KordowerJH, BennettDA
(2006) Substantia nigra tangles are related to gait impairment in older persons. Ann Neurol59, 166–173.
